Presbyopia Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio

Presbyopia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Presbyopia treatment therapies, analyzes DelveInsight.

Presbyopia Overview:

Presbyopia is an age-related condition in which the eye's lens loses its ability to focus on nearby objects. It is the most common physiological change seen in adults and typically results in difficulty with near vision. People with presbyopia often experience eye strain and headaches, and may hold objects further away to see them clearly. The most common solution is the use of reading glasses. The prevalence of presbyopia in low- and middle-income countries is not well-documented, as most studies on refractive errors in these regions have focused on distance vision. The exact cause of presbyopia is still debated, but the most widely accepted explanation is the increased stiffness of the crystalline lens. This condition leads to a gradual decline in the eye's ability to accommodate, making reading at the usual distance progressively more difficult. Patients around the age of 40 often notice trouble reading at a standard distance, but they may experience improvement if the reading distance is extended slightly. In the early stages, headaches are common, and those who spend a lot of time in front of screens may experience symptoms sooner due to latent accommodative dysfunction.

Download our report @ https://www.delveinsight.com/report-store/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Presbyopia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Presbyopia Therapeutics Market.

Key Takeaways from the Presbyopia Pipeline Report

DelveInsight's Presbyopia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Presbyopia treatment.
LENZ Therapeutics has submitted a New Drug Application (NDA) for LNZ100, a preservative-free, single-use, once-daily eye drop containing aceclidine. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025. LNZ100 aims to provide a pupil-selective and long-acting therapeutic option for presbyopia. ​
Orasis Pharmaceuticals received FDA approval for Qlosi in October 2023. This low-dose, preservative-free eye drop can be administered up to twice daily, with effects lasting up to 8 hours. It is designed to offer a gentler option with potentially fewer side effects compared to higher-dose alternatives. ​
Key Presbyopia companies such as Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio, and others are evaluating new drugs for Presbyopia to improve the treatment landscape.
Promising Presbyopia therapies include LNZ100, GLK-302, and others.

Presbyopia Pipeline Analysis
The Presbyopia pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Presbyopia Market.

Categorizes Presbyopia therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Presbyopia drugs under development based on:

Stage of development

Presbyopia Route of administration

Target receptor

Monotherapy vs. combination therapy

Presbyopia Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Presbyopia Licensing agreements

Funding and investment activities supporting future Presbyopia market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Presbyopia Emerging Drugs

LNZ100: Lenz Therapeutics

LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, a selective muscarinic receptor agonist that improves near vision by constricting the pupil. Unlike other similar treatments, aceclidine's unique mechanism reduces the risk of myopic shift and brow ache by separating the miotic effect from ciliary muscle stimulation. This makes LNZ100 an effective and long-lasting treatment for presbyopia, a condition causing gradual near vision decline due to lens hardening with age. The FDA has accepted the New Drug Application (NDA) for LNZ100, and it is currently in the registration stage of its clinical trials for presbyopia treatment.

GLK-302: Glaukos Corporation

Glaukos Corporation is developing GLK-302, a sterile ophthalmic cream containing pilocarpine for treating presbyopia. Applied to the eyelid, it delivers pilocarpine through the skin to the eye, where it constricts the pupil and improves near vision by increasing the depth of focus, without significantly affecting distance vision. GLK-302 is currently in Phase II of its clinical trial for presbyopia treatment.

Presbyopia Companies

Around 10 or more key companies are developing therapies for presbyopia. Among them, Lenz Therapeutics has drug candidates in the most advanced Phase III stage.

DelveInsight's report covers around 10+ products under different phases of Presbyopia clinical trials like

Presbyopia Late stage Therapies (Phase III)
Presbyopia Mid-stage Therapies (Phase II)
Presbyopia Early-stage Therapies (Phase I)
Presbyopia Pre-clinical and Presbyopia Discovery stage Therapies
Presbyopia Discontinued & Inactive Therapies

Presbyopia pipeline report provides the Presbyopia therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Presbyopia Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Presbyopia Therapies and Key Presbyopia Companies: Presbyopia Clinical Trials and recent advancements https://www.delveinsight.com/report-store/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Presbyopia Pipeline Therapeutic Assessment
• Presbyopia Assessment by Product Type
• Presbyopia By Stage
• Presbyopia Assessment by Route of Administration
• Presbyopia Assessment by Molecule Type

Download Presbyopia Sample report to know in detail about the Presbyopia treatment market @ Presbyopia Therapeutic Assessment https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Presbyopia Current Treatment Patterns
4. Presbyopia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Presbyopia Late-Stage Products (Phase-III)
7. Presbyopia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Presbyopia Discontinued Products
13. Presbyopia Product Profiles
14. Presbyopia Key Companies
15. Presbyopia Key Products
16. Dormant and Discontinued Products
17. Presbyopia Unmet Needs
18. Presbyopia Future Perspectives
19. Presbyopia Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Presbyopia Pipeline Reports Offerings: https://www.delveinsight.com/report-store/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.